A first-in-human gene therapy trial using a recombinant adeno-associated viral (rAAV) vector for acute intermittent porphyria (AIP) reveals that higher doses would be required to reach therapeutic levels of the porphobilinogen deaminase (PBGD) transgene. We developed a hyperfunctional PBGD protein to improve the therapeutic index without increasing vector dose. A consensus protein sequence from 12 mammal species was compared to the human PBGD sequence, and eight amino acids were selected. I291M and N340S variants showed the highest increase in enzymatic activity when expressed in prokaryotic and eukaryotic systems. In silico analysis indicates that isoleucine 291 to methionine and asparagine 340 to serine variants did not affect the active site of the enzyme. In vitro analysis indicated a synergistic interaction between these two substitutions that improve kinetic stability. Finally, full protection against a phenobarbital-induced attack was achieved in AIP mice after the administration of 1 × 10 11 gc/kg of rAAV2/8-PBGD-I291M/N340S vector; three times lower than the dose required to achieve full protection with the control rAAV2/8-hPBGD vector. In conclusion, we have developed and characterized a hyperfunctional PBGD protein. The inclusion of this variant sequence in a rAAV2/8 vector allows the effective dose to be lowered in AIP mice.
Introduction
Acute intermittent porphyria (AIP) is a metabolic disease characterized by hepatic deficiency of porphobilinogen deaminase (EC 2.5.1.61; PBGD), the third enzyme of heme synthesis pathway (1, 2) . It is thought to display autosomal dominant inheritance with incomplete penetrance (3) . A genetic defect at the PBGD locus generates a significant reduction in its activity. However, factors increasing hepatic heme demand induce up-regulation of hepatic aminolevulinate synthase (ALAS1), the first enzyme of the pathway, which in conjunction with a mutated PBGD leads to a marked overproduction and accumulation of δ-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are intermediate products between both enzymes. Clinical symptoms, associated with marked elevation of ALA and PBG levels, include severe abdominal pain, hypertension, tachycardia, nausea, vomiting, anxiety and problems with sleeping and concentrating. Most symptomatic patients experience one to several attacks during their lifetime, but approximately 5% of women and 3% of men with AIP suffer recurrent and frequent attacks with no identified precipitating factors (3) . This form of severe AIP is a devastating condition that significantly affects patients' quality of life and is associated with late complications such as hepatocellular cancer or kidney failure. Paresthesia and paralysis also occur, and death may result from respiratory paralysis. Orthotopic liver transplantation is the only curative treatment in these patients (4) and liver-gene therapy can be an alternative option to improve quality of life and reduce the significant morbidity associated with current therapies (5) .
In previous studies, we demonstrated that high expression of human PBGD (hPBGD) in about 5-10% of the hepatocytes was sufficient to fully protect against ALA and PBG accumulation during induced phenobarbital attacks (6, 7) . There is a crossmetabolization of heme precursors from non-transduced neighboring cells by the over-expressing PBGD hepatocytes that prevent the blood secretion of ALA and PBG (6, 8, 9) . The proof-of-concept was performed in AIP mice with a recombinant adeno-associated vector expressing PBGD (rAAV2/5 EalpAAT hPBGD) (10, 11) . In the first in humans phase 1 open-label, multi-center clinical trial, the administration of rAAV2/5-EalpAAT-hPBGD was found to be safe, but the overexcretion of heme precursors was not modified even in patients receiving the highest doses of the viral vector (1.8 × 10 13 genome copies/kg) (12) . Therefore, improving the therapeutic index of gene therapy vectors is an important goal. This study aimed at evaluating the development of new bioengineered PBGD variants capable of metabolizing the toxic heme precursors produced by the liver at an increased rate. To date, more than 400 different genetic mutations of PBGD have been reported worldwide, but to our knowledge, no PBGD protein with a greater catalytic capacity has been described.
Results
Eight bioengineered PBGD variants were selected after multiple sequence alignment of the ubiquitous PBGD enzyme in 12 species of mammals
The amino acid sequence of PBGD is highly conserved in mammals. Two isoforms have been reported, the housekeeping enzyme and the erythrocyte-specific enzyme (13) . The housekeeping enzyme has 17 extra residues in the N-terminal region that do not alter catalytic activity or the PBGD stability (14) . Thus, the 361 amino acids from the housekeeping PBGD sequence from 12 species of mammals were analyzed, and a consensus sequence was identified. This consensus sequence was then compared with the hPBGD sequence, and eight different amino acids were identified (Supplementary Material, Fig. 1 ).
Eight bioengineered PBGD variants were analyzed in prokaryotic and eukaryotic systems and were found to display a higher enzymatic activity than the wild-type PBGD
The mutated PBGD sequences were cloned into the pET16B vector and transformed into Escherichia coli, BL21 (DE31) pLysS strain. The expression of the protein of interest was induced for three h by IPTG and the cell culture was centrifuged before the analysis of PBGD activity in the bacterial pellet. Enzymatic activity was normalized per milligram of protein. PBGD variants mutated in H120Y, I291M, N340S and S344N presented the highest increase in enzymatic activity in a prokaryotic system, although the PBGD-I291M and PBGD-N340S showed the largest increase (Fig. 1A) as compared to non-mutated hPBGD.
Catalytic performance of these eight PBGD variants was also analyzed in a eukaryotic system. The cDNA sequences were cloned into a pTRE vector, and the plasmids were injected into several groups of mice by hydrodynamic injection (n = 5). Twenty-four h after the procedure, liver samples were analyzed to quantify hepatic PBGD activity (Fig. 1B) . The PBGD variants presenting the largest increase in activity were PBGD-H120Y, PBGD-H199Q, PBGD-I291M and PBGD-N340S. Interestingly, the PBGD-N340S variant showed the highest PBGD activity, a 4-fold increase when compared to the wild-type (Fig. 1B) .
In order to identify a synergic effect between the different modifications of the amino acids, new constructions were performed containing the cDNA sequences modified in the amino acids that showed the largest increase in the PBGD activity (N340S) plus one of the other modifications (H120Y, H199Q or I291M). These plasmids were injected into four groups of mice (n = 4) by hydrodynamic injection, and the increase in the hepatic PBGD activity was analyzed 24 h later. As controls, two groups of five AIP mice were injected with PBGD-N340S or hPBGD (Fig. 1C) .
PBGD-I291M/N340S showed the largest increase of the enzymatic activity in the liver samples (Fig. 1C ). This PBGD variant showed an enzymatic activity 2-fold higher than PBGD-N340S, which had already showed a 4-fold higher activity than hPBGD (Fig. 1B) . The proteins extracted from the liver samples were then analyzed by western blot. Figure 1D -E shows that liver expression of the hPBGD, PBGD-N340S, PBGD-I291M/N340S and PBGD-H199Q/N340S were similar across the animals while the construction that showed the highest increase in enzymatic activity was PBGD-I291M/N340S. As observed in Supplementary  Figure 1 In vitro catalytic performance and thermodynamic stability of selected purified proteins
The purified protein variants exhibiting the highest PBGD activity were characterized in vitro to determine their stability and catalytic constants (Fig. 2) . Consistently, PBGD-H120Y variant displayed the highest activity ( Fig. 2A) while hPBGD, Figure 1 . The change in certain amino acids in the PBGD sequence induced an increase in the catalytic activity of the enzyme. PBGD enzyme was mutated at positions S45L, H120Y, R164K, H199Q, I291M, Q332E, N340S or S344N generating eight different PBGD variants. Bio-engineered PBGD proteins were compared to the human housekeeping PBGD in a (A) prokaryotic system and (B) eukaryotic system. The synergic effect of the N340S variant with H120Y, H199Q or I291M were assayed by measuring (C) enzymatic activity and (D, E) protein content by immunoblot. * , P-value<0.05; * * , P-value<0.01; * * * P-value<0.001 versus hPBGD plasmid. $, P-value<0.05.
PBGD-H199Q and PBGD-N340S showed similar catalytic performance (Fig. 2B) .
Kinetic stability is a measure of the resistance of the protein to aggregate over time, and is a good marker of intracellular protein homeostasis (10) . In our case, the PBGD-H120Y protein exhibited thermodynamic stability in the three domains with respect to the native protein but a loss of cooperativity in the unfolding of domain 1 (Fig. 2C ). PBGD-H199Q (Fig. 2D ) and PBGD-N340S (data not shown) proteins showed similar thermodynamic stability to wild-type (wt) protein. Finally, PBGD-I291M/N340S increased its kinetic stability in more than 20% as compared to hPBGD when tested at physiological temperature (Fig. 2E) . Furthermore, the thermodynamic stability of PBGD-I291M/N340S increased by 4
• (from 70-74
• C) as compared to hPBGD (data not shown) indicating that the overall fold becomes more stable upon mutation. Importantly, the increase in stability was also manifested in an increase of in vitro enzyme activity (5% in the turnover rate), which can be attributed to the enhanced stability of the biomolecule during the enzyme assay (Fig. 2E ).
In silico analysis of the mutations in the PBGD sequence
The quaternary structure of the protein was analyzed in silico by molecular modeling and molecular dynamics (Fig. 3 ). This showed that none of the modified amino acids in the PBGD-I291M/N340S affects the active site of the enzyme (Fig. 3A) . The N340 position is in an α-helix in the C-terminal end. Since both amino acids (asparagine and serine) are polar amino acids, the N304S modification did not change the α-helix configuration. However, the smaller size of the serine side chain could permit higher mobility of this α-helix structure (red in the Fig. 3 ). Furthermore, the modification in amino acid I291M affected a β-sheet structure (in green in Fig. 3 ) that interacts with the α-helix from the C-terminal end (blue circle in Fig. 3B ). Both amino acids (methionine and isoleucine) carry non-polar side chains but methionine is less non-polar, and the loss of hydrophobicity could affect the interaction between the α-helix and the β-sheet, increasing the mobility of the α-helix and easing the entrance of the first monopyrrol into the active site of the enzyme.
Therapeutic efficacy of adeno-associated viral 2/8 vector carrying the new PBGD variant
Adeno-associated viral 2/8 (AAV2/8) vectors carrying the sequence of PBGD variants showing the highest in vitro activity (PBGD-H120Y) or the strongest kinetic stability (PBGD-I291M/ N340S) were constructed and produced. Thus, AAV2/8-EalpAAT-PBGD-H120Y and AAV2/8-EalpAAT-PBGD-I291M/N340S were analyzed to evaluate their therapeutic efficacy to prevent an acute attack in AIP mice (Fig. 4) . As a control, an AAV2/8-EalpAAThPBGD expressing the human protein was also produced. AIP male mice were injected with different AAV2/8 vectors at doses ranging from 1 ×10 11 to 3.3 ×10 11 genome copies (gc)/kg.
Twelve days post-injection, 4-6 animals/group were sacrificed and hepatic DNA vector content was analyzed and expressed as fold change of endogenous PBGD DNA copies. The median dose of the AAV2/8-EalpAAT-PBGD-I291M/N340S was not tested. As expected, a dose-dependent increase of DNA vector content was observed (Fig. 4A) and its content was similar in all the animals injected with the same dose, regardless of the transgene. Therefore, it was possible to compare the effects of the different variants developed in the protection against an induced biochemical attack in AIP mice. Two and six weeks post-injection mice were injected with four increasing doses of phenobarbital to induce acute attacks. As control groups, non-injected WT and AIP were also challenged with phenobarbital. Twenty-four h urine samples were collected at the end of each phenobarbital administration to measure ALA and PBG excretions. Urine excretion of porphyrin precursor after the second phenobarbital challenge is presented in Figure 4B and C. A consistently high porphyrin excretion was observed in untreated AIP mice while no ALA and PBG accumulation was measured in WT mice. Of interest, AIP mice injected with the lowest dose of the vector (1 ×10 11 gc/kg) showed important excretion differences between the vectors. Thus, AAV2/8-EalpAAT-PBGD-I291M/N340S showed no precursor accumulation while animals injected with hPBGD and H120Y variants still displayed high amounts of PBG and ALA in urine ( Fig. 4C and D) . Full protection against phenobarbital challenge was obtained with the administration of 1 × 10 11 gc/kg AAV2/8-PBGD-I291M/N340S, 2 × 10 11 gc/kg AAV2/8-PBGD-H120Y and 3 × 10 11 gc/kg control AAV2/8-hPBGD. Animals were sacrificed 54 days post-injection, and hepatic PBGD activity was analyzed (Fig. 4D) . At the dose 1 × 10 11 gc/kg, PBGD activity was three times higher in the group of mice injected with a vector containing the I291M/N340S variant when compared to animals receiving vector carrying the wildtype hPBGD or the H120Y variant. These results suggest that the administration of the PBGD-I291M/N340S variant reduced by three the AAV dose required to achieve full protection against a phenobarbital-induced attack in AIP mice. Although the PBGD-H120Y variant showed a higher in vitro catalytic capacity, it did not significantly improve the therapeutic capacity of the AAV vector.
Discussion
Liver transplantation represents the only cure for patients who suffer from severe acute attacks (15) , associated with chronic accumulation of potential neurotoxic porphyrin precursors. The siRNA ALAS1 is an efficient treatment option to prevent high accumulation of these porphyrin precursors which is currently being tested in phase III clinical trial (Givosiran, Alnylam, https://www.businesswire.com/news/home/20180413005605/en/). Givosiran generated a transient blockade on the expression of the ALAS1 hepatic gene. It remains to be determined whether the effect of the prolonged blockade of hepatic heme synthesis could modify excretion of hydrophobic and toxic compounds and increase the sensitivity to drugs and other triggering factors associated with acute attacks. An alternative therapeutic option is the overexpression of PBGD in the hepatocytes as the liver of these patients is completely normal except for PBGD deficiency (16) . This alternative represents not only a safe but also the simplest etiological alternative for AIP as previously demonstrated in experimental models (6, 9, 11, 17, 18) . Transient expression of therapeutic proteins in the hepatocytes can be achieved by modified mRNA technology. However, as in the case of the siRNA, recurrent administrations of the drug are required. AAV vectors allow long-term expression of the therapeutic protein after a single administration. Therefore, this therapeutic alternative is especially suited for those patients with recurrent acute porphyria attacks. However, intravenous administration of up to 1.8 × 10 13 genome copies/kg rAAV2/5-EalpAAT-hPBGD in patients with severe AIP failed to diminish PBG and ALA overexcretion associated with the clinical symptoms of the disease. Given that the risk of cellular immune response to AAV vector capsid is dose dependent (12), we developed an AAV encoding a new bioengineered PBGD aiming to decrease vector dose. PBGD catalyzes the formation of linear tetrapyrrole hydroxymethylbilane by condensing four PBG pyrroles in a multistep reaction (19) . It is a monomeric enzyme organized in three domains. Domain 1 (residues 1-116 and 216-239) and domain 2 (residues 117-215) are connected by a hinge region that introduces flexibility, whereas the hydrophobic cleft that is formed between the two domains defines the active site (20) .
Prokaryotic and eukaryotic systems showed that the H120Y, H199Q, I291M and N340S PBGD variants increased PBG polymerization significantly, although PBGD-H120Y was the variant with enhanced enzyme kinetic as demonstrated in in vitro assays ( Fig. 2A) . Given that H120 has been proposed as a hinge region between Domains 1 and 2 (21) and the H120Y variant enhances enzyme kinetic, these results suggest that this Y substitution introduces changes in the cavity where PBG polymerization takes place. However, its kcat/K M rate was reduced when compared to wild-type protein suggesting defects in conformational stability. As a consequence, the expression of the PBGD-H120Y protein in a rAAV system only partially improves ALA and PBG metabolism.
A modified hPBGD protein comprising I291M and N340S amino acid substitutions increased in vitro kinetic stability by more than 20%. However, the I291 and N340 residues do not participate in the active site in the human housekeeping PBGD enzyme. Thus, the advantage of this variant could be explained because of faster incorporation of the first monopyrrol to the active site of the enzyme. The smaller size of the radical in serine could enable the mobility of the α-helix structure from the C-terminal end of the PBGD-N340S variant, together with a less non-polar substitution of I291M of the β-sheet structure leading to increased mobility of both structures, thus facilitating the entrance of the substrate. Our data suggest a synergistic effect after combined substitutions of I291M and N340S improving the catalytic activity of the enzyme without the formation of the Michaelis complex and the K M being affected.
A consistently better in vitro biophysical characteristic was shown with PBGD-I291M/N340S when compared to the hPBGD sequence in an AAV2/8 system. As a metabolic consequence, full protection against the phenobarbital-induced attack was obtained when 1 × 10 11 gc/kg of the vector carrying PBGD-I291M/N340S was injected, a dose three times lower than in AIP mice injected with AAV2/8-EalpAAT-hPBGD. One major concern for a potential translation to humans of a gene-based strategy with the new PBGD variant is the formation of antibodies against the new protein. Importantly, all eight patients developed anti-AAV5 neutralizing antibodies in the clinical trial, but no humoral or cellular response was observed against PBGD (12) . Neither did the overexpression of hPBGD for more than a year and a half in the liver of non-human primates injected with a third-generation adenovirus induce an immune response against the transgene (9) . Probably, the intracellular expression of hPBGD did not induce immune responses. Given that the macaque and the hPBGD differ in 2% of the sequence, this NHP model probably predicts an absence of response to the use of the new PBGD variant in humans.
In conclusion, a new bioengineered PBGD comprising two amino acid substitutions with respect to human housekeeping 
Materials and Methods

Multiple sequence alignment of ubiquitous PBGD enzyme
The full-length sequence of the ubiquitous PBGD enzyme from 12 species of mammals was downloaded from UniProt Protein Database (http://www.uniprot.org/) in FASTA format (Supplementary Material, Fig. 1 ) and aligned using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) with default parameters. A consensus sequence for PBGD was obtained, and the following eight different amino acids were identified when compared to hPBGD sequence: S45L, H120Y, R164K, H199Q, I291M, Q332E, N340S and S344N (Table 1) .
Generation of HMB-synthase constructions
The eight bioengineered variants and the hPBGD DNA sequences were cloned into the pET-16B expression vector (Novagen, Madison, WI). The vector was transformed into Escherichia coli BL21 (DE31) pLysS strain (Promega, Madison, WI) and PBGD transgene expression was induced by supplementing the culture medium with isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.05 M) (Invitrogen, Life Technologies, Madrid, Spain). Three hours later, enzymatic activity was measured in the bacterial pellet and normalized per milligram of protein. The sequence of the eight PBGD variants and the wild-type PBGD were also cloned in a pTRE-Tight vector (Clontech Laboratories, Inc, Heidelberg, Germany) driven by a liver-specific promoter human α-1-antitrypsin promoter with the human albumin enhancer (EalpAAT) (11). In vitro analysis of the thermodynamic and kinetic stability of the PBGD variants Circular dichroism measurements were taken as previously described (22) . Essentially, the experiments were collected in a JASCO J-815 spectropolarimeter, using a quartz cuvette of 0.2 cm path length. Sample concentration was 10 μM for all the proteins tested. Freshly purified PBGD samples at 4
• C were transferred to the spectropolarimeter, pre-stabilized to the target temperature and maintained at constant temperature until the decay reached a plateau. The isothermal unfolding rate (k NU ) was determined for each of the PBGD variants at physiological temperature and the time constant was extracted from the decay over time of the signal at 222 nm. Apparent melting temperatures were measured using temperature scans from 10-75
• C to ensure the appropriate determination of the baselines in both, the folded and unfolded states, with sample heating at 1 • C/min and monitored at 222 nm.
Data were analyzed using in-house built scripts programmed in 
In vitro determination of the catalytic activity of the PBGD enzyme variants
Enzymatic assays were performed as previously described (22) . Essentially, an aliquot of 10 μL of PBGD 150 μM in 48 μL of buffer (20 mm Tris-HCl pH 8, NaCl 150 mm) was pre-heated at 37
• C for 2 min. The assay started with the addition of 25 μL of substrate porphobilinogen (Frontier Scientific, Livchem Logistics GmbH, Frankfurt, Germany) diluted in the same buffer at different concentrations (ranging from 0.15 to 3.9 mm). The reaction was performed by incubation at 37
• C for 5 min and was then stopped by freezing the samples in liquid nitrogen. A control reaction without substrate PBG was also carried out. In order to transform the pre-uroporphobilinogen generated into uroporphobilinogen III, the samples were again incubated with 6 μL of U3S 25 mm for 30 min, and in darkness. The reaction was also stopped with liquid nitrogen. Uroporphyrinogens were then oxidized to uroporphyrins by adding 25 μL of I 2 in KI and incubation on ice for 10 min in darkness. The excess of iodine was removed with 25 μL of sodium metabisulfite (saturated solution), and the protein was precipitated by lowering the pH with 250 μL trichloroacetic acid (TCA, 10% w/v). Samples were centrifuged at 13 000 rpm for 5 min. The supernatant was diluted in HCl 0.1M for measuring the absorbance change at 405 nm in respect to the control sample.
In silico analysis of PBGD structure
The crystallographic protein structure was used as a starting structure for hPBGD (PDB code 3ECR). Based on this wt structure, the different mutants were introduced using the PyMOL mutagenesis toolbox (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.) and mutated PBGD proteins were used as initial structures for new simulations. The atomic structure was then solvated in a rectangular 73.82 × 84.85 × 87.24 Å 3 water box using the Solvate plug-in of VMD (23) . K + and Cl -ions were added to the system to achieve charge neutralization up to a final concentration of 120 mm. The CHARMM 36 force field (24) was employed to describe the molecular mechanics while the TIP3P model was used for water. Simulations ran for 50 ns. Following 20 000 steps of energy minimization, the atomic system was equilibrated for one ns. The pressure was kept constant at 1 atm by the Nosé-Hoover-Langevin piston, with a damping time constant of 50 ps and a period of 100 ps. The temperature was maintained at 303K by coupling the system to a Langevin thermostat, with a sampling coefficient of 1 ps -1 . The lengths of covalent bonds involving hydrogen atoms were constrained by the SETTLE algorithm in order to be able to use a two fs time step.
Animal model
The murine model of AIP (25) For the hydrodynamic procedure, 25 μg of pTRE-Tight plasmid carrying the different PBGD variants were injection into tail vein as previously described (7). Mice were sacrificed six days post-injection, and their livers were isolated to determine enzymatic PBGD activity and the amount of plasmid DNA in the liver samples.
Doses of 1 × 10 11 , 2 × 10 11 and 3.3 ×10 11 genomic copies/kg AAV2/8-EAlpAAT-hPBGD, AAV2/8-EAlpAAT-PBGD-H120Y or AAV2/ 8-EAlpAAT-PBGD-I291M/N340S were injected into male AIP mice (n = 4-6). Non-injected wt mice and AIP mice were used as control groups. To biochemically imitate a human porphyric attack, animals were administered with increasing doses of phenobarbital (75, 80, 85, 90 mg/kg body weight, intraperinoteally) for four consecutive days starting 16 and 42 days post-AAV injection. Therapeutic efficacy was assayed by daily urinary excretion of ALA, and PBG quantified using an ion exchange column method (BioSystems SA, Barcelona, Spain) and measured at 555 nm in an Ultrospec 3000 spectrophotometer (LS50B, PerkinElmer, Spain). Urinary precursor levels were normalized by urinary creatinine, as described by Unzu et al. (7) . At sacrifice, the liver was harvested and rinsed in ice-cold phosphate buffered saline. Samples for measurement of the plasmid DNA or for the detection of PBGD protein by immunoblot were frozen in liquid nitrogen until the extraction of DNA or protein. Quantification of plasmid DNA in liver samples and western blot analysis were performed as previously described (17) . PBGD activity was measured fluorometrically in fresh samples according to Anderson and Desnick (26) . Briefly, the liver sample was homogenized in lysis buffer (sodium phosphate buffer 1 mm pH 7.6, dithiothreitol 1 mm, Cl 2 Mg 1 mm and 0.05% Triton X-100) and centrifuged at 16 000 g for 20 min at 4
• C.
The supernatant was incubated in incubation buffer (Tris-HCl 0.1M pH 8.1 and DTT 0.1 mm) and 250 nmol of PBG (LivChem GmbH&Co.) in 1200 μL of total volume for one hour at 37
The enzymatic reaction was stopped with 175 μL of cold 40% TCA (Sigma, St Louis, MO) and the uroporphyrinogen formed was oxidized to uroporphyrin after 30 min of exposure to light. The concentration of uroporphyrins was determined by an LS50B spectrofluorometer (Perkin Elmer, Waltham, MA) with an excitation wavelength of 405 nm and an emission wavelength of 595 nm. PBGD activity was expressed in terms of pmol uroporphyrin/mg protein/h using appropriate standards.
Statistical analysis
Results were plotted as means ± standard deviation. The statistical analyses to compare differences between more than two groups were detected using a one-way ANalysis Of VAriance (ANOVA), and pairwise comparisons were made using Bonferroni's multiple comparison tests. Data were transformed using the formula log(1+x) in order to normalize the variances. The null hypothesis was rejected when P-value<0.05. Statistical analyses were carried out with GraphPad Prism 6.0 (GraphPad Software).
Supplementary Material
Supplementary Material is available at HMG online.
